Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | Chief Medical Officer | January 22, 2021 | January 26, 2021 |
| Q32 Bio Inc.QTTB · Entity 5594 | Chief Medical Officer | February 24, 2025 | February 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERCEPT PHARMACEUTICALS, INC.
Report date January 22, 2021 · Filed January 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,531 |
Reported balance
After 2021-01-22 transaction · row 1
1 source rowRow 1 · 2021-01-22 · Grant · Acquired 12,600 · Balance 20,531 F1: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2031-01-22 | Direct | 19,700 |
Reported balance
After 2021-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-22 · Grant · Acquired 19,700 · Balance 19,700 F2: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.
F2: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person.
Q32 Bio Inc.
Report date February 24, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,500 |
Reported balance
After 2025-02-24 transaction · row 1
1 source rowRow 1 · 2025-02-24 · Grant · Acquired 37,500 · Balance 37,500 F1: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.29 · Expires 2031-03-24 | Direct | 0 |
Reported balance
After 2025-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-24 · Disposition to issuer · Disposed 87,738 · Balance 0 F2: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2031-03-24 | Direct | 87,738 |
Reported balance
After 2025-02-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-24 · Grant · Acquired 87,738 · Balance 87,738 F4: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.29 · Expires 2031-12-16 | Direct | 0 |
Reported balance
After 2025-02-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-24 · Disposition to issuer · Disposed 17,951 · Balance 0 F2: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2031-12-16 | Direct | 17,951 |
Reported balance
After 2025-02-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-24 · Grant · Acquired 17,951 · Balance 17,951 F4: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.82 · Expires 2034-03-24 | Direct | 0 |
Reported balance
After 2025-02-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-24 · Disposition to issuer · Disposed 70,687 · Balance 0 F2: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2034-03-24 | Direct | 70,687 |
Reported balance
After 2025-02-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-24 · Grant · Acquired 70,687 · Balance 70,687 F4: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.
F2: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F3: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
F4: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2025 Filed Feb 27, 2025 02:57 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 70,687 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028252 · ownership.xml · derivative · entry 7 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,687 Underlying: Common Stock · 70,687 shares Expires 2034-03-24 F4 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 02:57 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,687 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-25-028252 · ownership.xml · derivative · entry 6 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,687 shares Expires 2034-03-24 F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 02:57 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 17,951 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028252 · ownership.xml · derivative · entry 5 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,951 Underlying: Common Stock · 17,951 shares Expires 2031-12-16 F4 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 02:57 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,951 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0000950170-25-028252 · ownership.xml · derivative · entry 4 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,951 shares Expires 2031-12-16 F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 02:57 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 87,738 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028252 · ownership.xml · derivative · entry 3 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,738 Underlying: Common Stock · 87,738 shares Expires 2031-03-24 F4 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 02:57 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 87,738 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0000950170-25-028252 · ownership.xml · derivative · entry 2 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,738 shares Expires 2031-03-24 F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 02:57 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028252 · ownership.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 F1 · kind: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:37 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 70,687 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-24-037392 · ownership.xml · derivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,687 Underlying: Common Stock · 70,687 shares Expires 2034-03-24 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 19,700 | $0.00 Strike: $29.46 | $0.00 |
DisclosureSEC source: 0001104659-21-007779 · tm214232-3_4seq1.xml · derivative · entry 2 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,700 Underlying: Common Stock · 19,700 shares Expires 2031-01-22 F2 · derivative.exercise_date: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 12,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-007779 · tm214232-3_4seq1.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,531 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 132 | $24.70 | $3,260.40 |
DisclosureSEC source: 0001104659-21-001121 · tm211606-3_4seq1.xml · nonDerivative · entry 2 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,931 F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 534 | $24.70 | $13,189.80 |
DisclosureSEC source: 0001104659-21-001121 · tm211606-3_4seq1.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,063 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 112 | $42.08 | $4,712.96 |
DisclosureSEC source: 0001104659-20-112322 · tm2032461d7_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,597 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 69 | $43.41 | $2,995.29 |
DisclosureSEC source: 0001104659-20-106199 · tm2030989d1_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,709 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,192 | $47.44 | $56,542.52 |
DisclosureSEC source: 0001104659-20-097335 · tm2029110d1_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,778 Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 112 | $46.52 | $5,210.24 |
DisclosureSEC source: 0001104659-20-081433 · tm2024073d3_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,970 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 70 | $77.40 | $5,418.00 |
DisclosureSEC source: 0001104659-20-074272 · tm2022724d1_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,082 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 112 | $58.40 | $6,540.80 |
DisclosureSEC source: 0001104659-20-043283 · tm2014981d2_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,152 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 69 | $71.82 | $4,955.58 |
DisclosureSEC source: 0001104659-20-034881 · tm2012973d1_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,264 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 170 | $96.24 | $16,360.80 |
DisclosureSEC source: 0001104659-20-024006 · tm209671d1_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,333 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 6,900 | $0.00 Strike: $99.66 | $0.00 |
DisclosureSEC source: 0001104659-20-007262 · tm205922d3_4.xml · derivative · entry 2 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 6,900 shares Expires 2030-01-23 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-007262 · tm205922d3_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,503 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 732 | $113.02 | $82,730.64 |
DisclosureSEC source: 0001104659-20-002350 · tm201539d1_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,303 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 150 | $123.92 | $18,588.00 |
DisclosureSEC source: 0001104659-20-001089 · tm201209d6_4.xml · nonDerivative · entry 2 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,035 F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 259 | $123.92 | $32,095.28 |
DisclosureSEC source: 0001104659-20-001089 · tm201209d6_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,185 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 154 | $119.45 | $18,395.30 |
DisclosureSEC source: 0001104659-19-075193 · tm1926766d1_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,444 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 15, 2019 Filed Dec 17, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 80 | $114.16 | $9,132.80 |
DisclosureSEC source: 0001104659-19-073503 · tm19264151_4.xml · nonDerivative · entry 1 Campagna Jason · CIK 0001793338 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,598 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.